CGEN
Compugen·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 2
Bearish signal 4
MACD Golden Cross
Ample Liquidity
Negative Gross Margin
Significant Net Income Decline
Bearish Abandoned Baby
Revenue Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About CGEN
Compugen Ltd.
A developer of Fc fusion therapeutic proteins and mono clonal antibodies for cancer and immune-related disease
Azrieli Center, 26 Harokmim Street, Building D, Holon 5885849 Israel
Focus on the development of therapeutic proteins and monoclonal antibodies.
Compugen Ltd., established on February 10, 1993, is an Israeli company. The company is a clinical-stage therapeutic discovery and development company that leverages widely applicable predictive computational discovery capabilities to identify new drug targets and new biological pathways to develop treatments in the field of cancer immunotherapy. The company's innovative immuno-oncology pipeline consists of three clinical-stage projects, targeting immune checkpoint discoveries by computing COM 701, COM 902 and rilvegostomig. The Company's lead product candidates COM701 (a potential first-in-class anti-PVRIG antibody) and COM902 (a potential best-in-class therapeutic anti-TIGIT antibody) are in Phase 1 clinical trials and have been evaluated for the treatment of solid tumors, As a monotherapy and a combination therapy blocked by dual (PVRIG/PD-1, PVRIG/TIGIT) and triple (PVRIG/PD-1/TIGIT).
Earnings Call
Q1/2025
Estimate EPS-0.05
Actual EPS-0.08
Estimate Revenue3.70M
Actual Revenue2.30M
Compugen's 2025 Q1 Earnings Call: Unpacking Key Contradictions in Ovarian Cancer Trials
May 19,2025 10:35
Earnings Decrypt
Earnings Decrypt
Q2/2025
Estimate EPS-0.09
Actual EPS-0.08
Estimate Revenue3.95M
Actual Revenue1.26M
Compugen's Q2 2025: Contradictions Uncovered in COM701 Trial Progress and Market Potential
Aug 06,2025 05:28
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
CGEN has released its 2025 Q3 earnings. EPS was reported at -0.07, versus the expected -0.09, beating expectations. The chart below visualizes how CGEN has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
CGEN has released its 2025 Q3 earnings report, with revenue of 1.89M, reflecting a YoY change of -88.96%, and net profit of -6.98M, showing a YoY change of -646.94%. The Sankey diagram below clearly presents CGEN's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
